Mirati Therapeutics (Mirati Therapeutics) Pre-Tax Income : $-725.62 Mil (TTM As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Mirati Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Mirati Therapeutics's pretax income for the three months ended in Sep. 2023 was $-161.90 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2023 was $-725.62 Mil. Mirati Therapeutics's pretax margin was -987.22%.

During the past 13 years, Mirati Therapeutics's highest Pretax Margin was -761.40%. The lowest was -6394.48%. And the median was -2671.57%.

Mirati Therapeutics Pre-Tax Income Historical Data

The historical data trend for Mirati Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirati Therapeutics Pre-Tax Income Chart

Mirati Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Pre-Tax Income

Get a 7-Day Free Trial

-98.42

-213.26

-357.94

-578.49

-740.36

Mirati Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Pre-Tax Income	Get a 7-Day Free Trial															-173.31	-202.22	-184.59	-176.91	-161.90

Competitive Comparison of Mirati Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Mirati Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mirati Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mirati Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Mirati Therapeutics's Pre-Tax Income falls into.

Mirati Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Mirati Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-759.589	+	19.23	+	0	+	0	+	0
	=	-740.36

Mirati Therapeutics's Pretax Income for the quarter that ended in Sep. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-172.054	+	10.15	+	0	+	0	+	0
	=	-161.90

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-725.62 Mil.

Mirati Therapeutics (NAS:MRTX) Pre-Tax Income Explanation

Mirati Therapeutics's Pretax Margin for the quarter that ended in Sep. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-161.904	/	16.4
	=	-987.22%

During the past 13 years, Mirati Therapeutics's highest Pretax Margin was -761.40%. The lowest was -6394.48%. And the median was -2671.57%.

Mirati Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Mirati Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Mirati Therapeutics (Mirati Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirati Therapeutics Inc (NAS:MRTX) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

26M:Germany

Address

3545 Cray Court, San Diego, CA, USA, 92121

Website

https://www.mirati.com

Mirati Therapeutics Inc is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer. It operates in a single geographical segment being the United States.

Executives

Jamie Christensen	officer: Sr. Vice President, Chief Scie	C/O MIRATI THERAPEUTICS, INC., 9393 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Benjamin Hickey	officer: EVP, Chief Commercial Officer	C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121
Aaron Ondrey	officer: Interim CFO	3545 CRAY COURT, SAN DIEGO CA 92121
Boxer Capital, Llc	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Christopher Fuglesang	other: See remarks	11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Shehan Bharatha Dissanayake	other: See remarks	11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Aaron I. Davis	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Mva Investors, Llc	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc.	other: See remarks	CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Joseph Lewis	other: See remarks	PO BOX N7776, LYFORD BAHAMAS
Faheem Hasnain	director	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John B Moriarty	officer: Chief Legal Officer	ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Carol Giltner Gallagher	director	C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Laurie Stelzer	officer: CFO	6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Julie M Cherrington	director	9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121